Investigational drug · Phase 2
SKB571
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Cancer (Non-Small Cell), Non-Small Cell Lung Cancer, Gastrointestinal Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
7
Any phase or sponsor naming "SKB571"
First trial start
2026
Jan 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB571", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Cancer (Non-Small Cell)
- Non-Small Cell Lung Cancer
- Gastrointestinal Tumors
- Pancreatic Cancer
- HNSCC
- Non-small Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB571" as an intervention, largest first.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07230405 · 295 participants (planned) · Start Jan 19, 2026 · Primary completion Jan 19, 2028
Drug: SKB571 for injection · For: Lung Cancer (Non-Small Cell)
Sites: Guangzhou, China; Zhengzhou, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07564466 · 160 participants (planned) · Start May 20, 2026 · Primary completion Aug 31, 2027
Drug: SKB571 for injection · For: Gastrointestinal Tumors
Sites: Chongqing, China; Fuzhou, China; Xiamen, China · 26 sites in all
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07622186 · 150 participants (planned) · Start Jul 15, 2026 · Primary completion Dec 31, 2028
Drug: SKB571 for injection; Osimertinib and 4 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 27 sites in all
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT06725381 · 138 participants (planned) · Start Dec 17, 2024 · Primary completion Dec 2026
Drug: SKB571 · For: Solid Malignancies
Sites: Guangzhou, China; Nanning, China; Wuhan, China · 15 sites in all
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07668154 · 120 participants (planned) · Start Jul 27, 2026 · Primary completion Sep 30, 2028
Drug: SKB571; Pembrolizumab and 2 more · For: HNSCC
Sites: Chengdu, China; Shanghai, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07308106 · 70 participants (planned) · Start Apr 3, 2026 · Primary completion Jun 30, 2027
Drug: SKB571 for injection · For: Non-small Lung Cancer
Sites: Shanghai, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07814066 · 30 participants (planned) · Start Oct 31, 2026 · Primary completion Feb 28, 2028
Drug: SKB571 · For: Pancreatic Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lung Cancer (Non-Small Cell)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.